Bioregenx (BRGX) Equity Average (2022 - 2026)

Bioregenx's Equity Average history runs 5 years deep, the most recent figure standing at -$4.5 million for Q1 2026.

• In Q1 2026, Equity Average fell 30.73% year-over-year to -$4.5 million; the TTM figure through Mar 2026 stood at -$4.5 million (down 30.73% YoY), while the FY2025 annual figure was -$4.0 million, down 45.24% from the prior year.
• Equity Average was -$4.5 million for Q1 2026 at Bioregenx, down from -$4.1 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $14.7 million in Q2 2024 to a low of -$4.5 million in Q1 2026.
• Historically, Equity Average has averaged $522129.1 across 5 years, with a median of -$2.4 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Equity Average plunged 2560.67% in 2023, then soared 686.61% in 2024.
• A 5-year view of Equity Average shows it stood at -$1.4 million in 2022, then slumped by 78.76% to -$2.4 million in 2023, then jumped by 309.09% to $5.1 million in 2024, then plunged by 180.38% to -$4.1 million in 2025, then declined by 10.83% to -$4.5 million in 2026.
• The last three Equity Average figures came in at -$4.5 million (Q1 2026), -$4.1 million (Q4 2025), and -$3.7 million (Q3 2025), per Business Quant data.